Milestone Pharmaceuticals Submits Response To The FDA’s CRL For CARDAMYST (Etripamil) Nasal Spray For PSVT Following Type A Meeting
June 16 (Reuters) - Milestone Pharmaceuticals Inc MIST.O:
MILESTONE PHARMACEUTICALS SUBMITS RESPONSE TO THE FDA’S CRL FOR CARDAMYST (ETRIPAMIL) NASAL SPRAY FOR PSVT FOLLOWING TYPE A MEETING
MILESTONE PHARMACEUTICALS INC - FDA TO DETERMINE ACCEPTANCE OF RESPONSE AND PDUFA DATE WITHIN 30 DAYS
MILESTONE PHARMACEUTICALS INC - REVIEW TIME EXPECTED TO BE WITHIN 2 OR 6 MONTHS FROM RESUBMISSION
MILESTONE PHARMACEUTICALS INC: BELIEVE TYPE A MEETING WITH FDA PROVIDED GUIDANCE TO SUBMIT RESPONSE TO CRL DIRECTLY AFTER MEETING
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Amazon 2026 Q1 Earnings Preview: AWS and Advertising Dual Engines Power Ahead, Can They Allay Market Doubts?

Google Bets $40B on Anthropic: Is Google Cloud the New Growth Engine as Meta Challenges Ad Dominance?

Citi Raises Brent Crude Forecast to $150: Strait of Hormuz Risks Brew, How High Can Oil Prices Rise?

Intel Posts Best Day Since 1987 as Nvidia Market Cap Reclaims $5 Trillion: Is the AI Trade Overstretched?

Is Meta Platforms Stock a Smart Buy Ahead of Q1 2026 Earnings? Unpacking AI Growth and Investment Potential

Tradingkey






